Non-Small Cell Lung Cancer (NSCLC)

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Progression-free survival lengths were different among patients with non-small cell lung cancer receiving sotorasib when stratified by genomic profile.

Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer.

Adjuvant atezolizumab led to disease-free survival benefit in patients with early-stage non–small cell lung cancer, including most patient subgroups, in the phase 3 IMpower010 trial.

Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.

Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.

The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.

Patients with EGFR-mutated non–small cell lung cancer who were treated with ado-trastuzumab emtansine and osimertinib experienced minimal anti-tumor outcomes.

Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.

Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.

Patients with EGFR-positive non–small cell lung cancer whose disease is not suitable for standard EGFR TKI monotherapy had promising responses and experienced few dose-limiting toxicities with pelcitoclax plus osimertinib.

Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.

Data from the ARROW study demonstrated safety and efficacy of pralsetinib in a cohort of Chinese patients with RET fusion–positive non–small cell lung cancer.

In a phase 1/2 trial, the selective targeting of EGFR exon 20 insertion mutations with mobocertinib in patients with previously treated non–small cell lung cancer resulted in superior patient-reported outcomes.

Findings from the phase 2 NRG-LU001 trial indicated that the addition of metformin to radiotherapy did not improve survival outcomes in patients with non–small cell lung cancer.

A 3-arm randomized study indicated that domvanalimab-based combinations yielded a promising overall response rate for patients with metastatic non–small cell lung cancer with a PD-L1 status of 50% or more.

The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.

Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.

Black patients with non–small cell lung cancer were more likely to be diagnosed at advanced stages of disease, less likely to receive surgery in early stages, and had increased cancer mortality rates than White patients.

Investigators advise against the use metformin in addition to chemoradiotherapy for patients with locally advanced non–small cell lung cancer due to progression-free survival and overall survival was not substantial.

Results of the phase 3 EMPOWER-Lung 3 trial support the use of cemiplimab in advanced or metastatic non–small cell lung cancer.

Patients with EGFR wild-type non–small cell lung cancer experienced a survival benefit with the addition of plinabulin to docetaxel in the second- and third-line settings.

Atezolizumab, which previously demonstrated positive results in the IMpower010 trial, was granted a priority review by the FDA for use in non–small cell lung cancer.

For patients with pIIIA-N2 non–small cell lung cancer, postoperative radiotherapy after complete resection and adjuvant chemotherapy did not positively impact disease-free survival.